Best AAV / Gene Therapy CDMOs in United States
38
CDMOs tracked
31
Fully scored
14
With FDA records
36
FDA inspections
103
EMA/MHRA GMP certs
For US-manufactured aav / gene therapy programs, Charles River Laboratories, Pharmaron Biologics, and Ajinomoto Bio-Pharma Services lead CDMO Signal's ranking of aav / gene therapy CDMOs with confirmed US facilities. Filtered from the global directory of 56 scored aav / gene therapy CDMOs to 31 with US manufacturing presence. US-based manufacturing carries specific advantages for sponsors filing under FDA jurisdiction: FDA inspection records — which form the core of the Signal Score's Quality Compliance pillar — apply directly, and QP release complexity common to EU-manufactured material does not apply. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.
Adeno-associated virus (AAV) is the dominant delivery platform for in vivo gene therapy, from rare-disease programs to larger systemic indications. Rising demand has pushed CDMOs to scale suspension processes and tighten full/empty capsid analytics.
Selecting an AAV CDMO hinges on serotype experience, suspension vs adherent platform, full/empty capsid separation, and a proven regulatory record. The rankings below score each manufacturer on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 16 NAI (no action), 20 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (35), United States (32), UNITED KINGDOM (23), Austria (9), Ireland (9).
Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 2 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 3 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
85.6 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 4 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
83.7 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 5 |
KB
KBI Biopharma
Durham, NC · Boulder, CO
|
83.5 | 100.0 | 1 insp · 1 GMP | Limited | 0 programs |
| 6 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
83.5 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 7 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
83.1 | 97.9 | 5 insp · 10 GMP | Available | 2 programs |
| 8 |
DH
Danaher (CGT Portfolio)
Washington, DC
|
81.5 | — | — | — | 0 programs |
| 9 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
81.0 | 98.8 | 4 insp · 8 GMP | — | 0 programs |
| 10 |
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
|
80.8 | 100.0 | 0 insp · 8 GMP | Available | 0 programs |
| 11 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
| 12 |
TK
Takeda
Boston, MA · Zurich, CH
|
80.5 | 99.3 | 4 insp · 18 GMP | — | 100 programs |
| 13 |
AG2
August Bioservices
San Carlos, CA
|
77.4 | 98.5 | 1 insp · 0 GMP | — | 0 programs |
| 14 |
CI
Cincinnati Children's Vector Production Facility
Cincinnati, OH
|
75.2 | 100.0 | 1 insp · 0 GMP | — | 1 programs |
| 15 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
75.1 | 79.3 | 1 insp · 0 GMP | Available | 0 programs |
| 16 |
CG
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
|
74.0 | — | — | — | 0 programs |
| 17 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
72.8 | 95.1 | 1 insp · 0 GMP | Limited | 0 programs |
| 18 |
VE
Vigene Biosciences
Rockville, MD
|
72.5 | — | — | — | 0 programs |
| 19 |
EM
Emergent BioSolutions (CGT)
Baltimore, MD
|
71.0 | — | — | — | 4 programs |
| 20 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
70.7 | 84.1 | 3 insp · 0 GMP | Available | 0 programs |
| 21 |
AN
Andelyn Biosciences
Columbus, OH
|
63.0 | — | — | Available | 0 programs |
| 22 |
UM
MassBiologics
Boston, MA
|
63.0 | — | 1 insp · 0 GMP | — | 0 programs |
| 23 |
FB
Forge Biologics
Columbus, OH
|
62.7 | — | — | 3 programs | |
| 24 |
MS
Made Scientific
Princeton, NJ
|
61.5 | — | — | — | 0 programs |
| 25 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
60.5 | — | — | — | 0 programs |
| 26 |
AB
Asklepios BioPharmaceutical (AskBio)
Research Triangle, NC · San Sebastian, ES
|
59.7 | — | — | — | 10 programs |
| 27 |
MA
Matica Biotechnology
College Station, TX
|
59.0 | — | — | Available | 0 programs |
| 28 |
VB
VintaBio
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 29 |
WB
Waisman Biomanufacturing
Madison, WI
|
59.0 | — | — | — | 0 programs |
| 30 |
EB
ElevateBio BaseCamp
Waltham, MA
|
59.0 | — | — | — | 0 programs |
| 31 |
VM
Vector BioMed
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| — |
Rose BioSolutions
Wilmington, MA
|
Profiled | — | — | — | 0 programs |
| — |
Orphan Therapeutics Accelerator (OTXL)
Cambridge, MA
|
Profiled | — | — | — | 0 programs |
| — |
Porton Advanced
Cranbury, NJ
|
Profiled | — | — | — | 0 programs |
| — |
Vantage Vector (Demo)
Gaithersburg, MD
|
Profiled | — | — | Available | 0 programs |
| — |
Advanced BioScience Laboratories, Inc. (ABL Inc.)
Rockville, MD
|
Profiled | — | — | — | 0 programs |
| — |
Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A)
Novato, CA
|
Profiled | — | — | — | 0 programs |
| — |
Landmark Bio
Watertown, MA
|
Profiled | — | — | — | 0 programs |
What to evaluate in a AAV / Gene Therapy CDMO
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
FDA jurisdiction — how the ranking scores US-based CDMOs
The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.
Which US CDMOs also cover EU and UK regulatory geographies?
Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.
How CDMO Signal identifies US manufacturing presence
Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.
AAV / Gene Therapy CDMOs — Frequently Asked Questions
Who are the top AAV / Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked AAV / Gene Therapy CDMOs include Charles River Laboratories, Pharmaron Biologics, Ajinomoto Bio-Pharma Services. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many AAV / Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 14 AAV / Gene Therapy CDMOs with FDA inspection records and 103 EMA/MHRA GMP certificates across the group.
What should I look for in an AAV CDMO?
Look for serotype experience, a scalable suspension platform, strong full/empty capsid analytics, and a clean FDA and EMA/MHRA record. Match validated bioreactor scale to your dose and indication.
What's the difference between AAV and lentiviral CDMOs?
AAV is non-integrating and produced at higher volumes for in vivo gene therapy. Lentivirus integrates into the genome, is made under BSL-2 with RCL testing, and is used mainly for ex vivo cell engineering like CAR-T.
Related modalities